"Meningococcal disease"

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management NICE guideline Published: 19 March 2024 www.nice.org.uk/guidance/ng240 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility ) and meningococcal disease: recognition, diagnosis and management(NG240)© NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of93Contents Overview ......................................................................................................................................6 Who

Meningococcal disease Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageMeningococcal disease MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:28 May 2023Last updated:21 Jun 2023SummaryMeningococcal disease is an acute contagious life-threatening illness, characterised by fever sterile site.[1] Probable cases include those where N meningitidis antigen is detected by immunohistochemical staining on formalin-fixed tissue, or in cerebrospinal fluid by latex agglutination.This topic covers meningococcal disease (meningococcal meningitis and/or meningococcal sepsis) and bacterial meningitis in non-pregnant adults and children. See also Bacterial meningitis in adults.History

Rapid Review: What are the risk factors for invasive meningococcal disease? Invasive Meningococcal Disease | National Collaborating Centre for Methods and Tools This browser does not support PDFs, or the PDF is too large to render. Please download the PDF: Download PDFThis browser does not support PDFs, or the PDF is too large to render. Please download the PDF: Download PDF

Meningococcal disease: guidance on public health management Meningococcal disease: guidance on public health management - GOV.UK Cookies on GOV.UKWe use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from Search 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Meningococcal disease: guidance on public health management Advice for health protection professionals on the management of meningococcal disease in the UK. From: UK Health Security Agency Published 1 March 2012 Last updated 8 October 2024 — See all updates Get emails about this page Documents

Meningococcal disease enhanced surveillance plan Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UKNavigation menuMenuSearch GOV.UKHomeHealth and social carePublic healthHealth protectionImmunisationGuidanceMeningococcal disease enhanced surveillance planThe national surveillance protocol for invasive meningococcal disease in EnglandFrom:UK Health Security AgencyPublished28 August 2015Last updated15 December 2022 — See all updatesGet emails about this pageApplies

Bacterial meningitis and meningococcal disease CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If

Meningococcal disease and ciprofloxacin: PGD template Meningococcal disease and ciprofloxacin: PGD template - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver account: sign in 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Infectious diseases Guidance Meningococcal disease and ciprofloxacin: PGD template Patient group direction (PGD) template to supply or administer ciprofloxacin for meningococcal disease clusters in educational or residential settings.From: Public Health England Published 17 February 2017 Last updated 11

Meningococcal disease: guidance on public health management Guidance for public health management of meningococcal disease in the UK Updated August 2019 Guidance for public health management of meningococcal disease in the UK: updated August 2019 2 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Published August 2019 PHE publications PHE supports the UN Gateway number: GW-599 Sustainable Development Goals Guidance for public health management of meningococcal disease in the UK

Geographical and temporal variations of serogroups and clonal types of Neisseria meningitidis involved in culture-confirmed invasive meningococcal disease in Canada, 2015-2023. Invasive meningococcal disease (IMD) is a nationally notifiable illness in Canada due to its potential severity and transmissibility. Vaccination strategies differ by province/territory and are informed by changes

Evaluating the Efficacy of a Serious Game to Deliver Health Education About Invasive Meningococcal Disease: Clustered Randomized Controlled Equivalence Trial. Invasive meningococcal disease (IMD) is a serious, vaccine-preventable infectious disease that can be life-threatening. Teaching adolescents about the early detection and prevention of IMD can be challenging in a school environment

Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020). Invasive meningococcal disease belongs among the most dangerous infectious diseases in the world. Several polysaccharide conjugate vaccines against serogroups A, C, W and Y are available and two recombinant peptide vaccines against serogroup B . meningitidis isolates from invasive meningococcal disease covering 28 years. Serogroup B isolates (MenB) showed high heterogeneity and the most common clonal complexes were cc18, cc32, cc35, cc41/44, and cc269. Isolates of clonal complex cc11 were predominately serogroup C (MenC). The highest number of serogroup W isolates (MenW) belonged to clonal complex cc865, which we described as exclusive to the Czech

Differences in meningococcal disease incidence by health insurance type and among persons experiencing homelessness-United States, 2016-2019. Meningococcal disease is a serious but rare disease in the United States. Prior publications suggest incidence differs among privately vs publicly-insured persons, and that incidence is higher among persons experiencing homelessness (PEH) than persons not known to be experiencing homelessness (non-PEH). Using insurance claims data for persons aged <1 to 64 years, we calculated meningococcal disease incidence among a population with employer-sponsored commercial insurance and persons enrolled in state Medicaid programs nationwide. We also examined meningococcal disease incidence by PEH status in Medicaid data. From 2016 through 2019, persons who met our

Meningococcal disease Meningococcal disease - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates ), or by isolation of N meningitidis from a normally sterile site.[1]Centers for Disease Control and Prevention. Meningococcal disease. In: Manual for the surveillance of vaccine-preventable diseases. December 2019 [internet publication].https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html Probable cases include those where N meningitidis antigen is detected by immunohistochemical staining on formalin

Meningococcal disease Meningococcal disease - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates ), or by isolation of N meningitidis from a normally sterile site.[1]Centers for Disease Control and Prevention. Meningococcal disease. In: Manual for the surveillance of vaccine-preventable diseases. December 2019 [internet publication].https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html Probable cases include those where N meningitidis antigen is detected by immunohistochemical staining on formalin

Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex. To identify recent trends in invasive meningococcal diseases (IMD) in Quebec, Canada, with a focus on MenY cases and MenY strains. IMD cases and MenY strains from January 1, 2015 to August 11

Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021-2022. In 2022, concurrent outbreaks of hepatitis A, invasive meningococcal disease (IMD), and mpox were identified in Florida, USA, primarily among men who have sex with men. The hepatitis A outbreak (153 cases) was associated with hepatitis A virus genotype IA. The IMD outbreak (44 cases mpox cases than among hepatitis A (21%) or IMD (34%) cases. Where feasible, vaccination against hepatitis A, meningococcal disease, and mpox should be encouraged among at-risk groups and offered along with program services that target those groups.

Obstetric and Neonatal Invasive Meningococcal Disease Caused by Neisseria meningitidis Serogroup W, Western Australia, Australia. Three mother-baby pairs with invasive meningococcal disease occurred over 7 months in Western Australia, Australia, at a time when serogroup W sequence type 11 clonal complex was the predominant local strain. One mother and 2 neonates died, highlighting the role

Serogroup B Invasive Meningococcal Disease in Older Adults Identified by Genomic Surveillance, England, 2022-2023. We report a cluster of serogroup B invasive meningococcal disease identified via genomic surveillance in older adults in England and describe the public health responses. Genomic surveillance is critical for supporting public health investigations and detecting the growing threat

Recent increase in atypical presentations of invasive meningococcal disease in France. Invasive meningococcal disease (IMD) cases declined upon the implementation of non-pharmaceutical interventions (NPI) (social distancing and mask wearing) to control the COVID-19 pandemic but rebounded in 2022 in numbers with genotypical changes of the strains. We explored here associated modifications

Follow-up care experience of patients with invasive meningococcal disease and their family caregivers: a qualitative study. Clinical guidelines recommend systematic follow-up of patients surviving invasive meningococcal disease (IMD) to assess sequelae. However, little is known about survivors and family caregivers' experiences of the follow-up care. Study sought to explore IMD survivors